Ganglioglioma is a rare form of low-grade glioma that mainly affects children and young adults. The low incidence of this tumor has precluded prospective studies of available treatment strategies. A large retrospective study has now examined the effectiveness of these strategies, specifically the influence of postoperative radiotherapy on patient outcome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lang, F. F. in Tumors of the Brain and Spine (eds Demonte, F., Gilbert, M. R., Mahajan, A. & McCutcheon, I. E.) 93–119 (Springer-Verlag, New York, 2007).
Giulioni, M. et al. Lesionectomy in epileptogenic gangliogliomas: seizure outcome and surgical results. J. Clin. Neurosci. 13, 529–535 (2006).
Rades, D. et al. The role of postoperative radiotherapy for the treatment of gangliogliomas. Cancer 116, 432–442 (2010).
Luyken, C. et al. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 101, 146–155 (2004).
Im, S. H. et al. Intracranial ganglioglioma: preoperative characteristics and oncologic outcome after surgery. J. Neurooncol. 59, 173–183 (2002).
Karim, A. B., Afra, D. & Cornu, P. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council Study BRO4: an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 52, 316–324 (2002).
van den Bent, M. J., Afra, D. & de Witte, O. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366, 985–990 (2005).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
M. P. Mehta is a stockholder in and on the board of directors for Pharmacyclics. He is also a stockholder in Tomotherapy, for which he acts as a consultant. He is on the speakers bureau for Schering Plough and acts as a consultant for this company, Genentech and Adnexus.
Rights and permissions
About this article
Cite this article
Mehta, M. Gangliogliomas—what is the appropriate management strategy?. Nat Rev Neurol 6, 190–191 (2010). https://doi.org/10.1038/nrneurol.2010.32
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.32
